Data on:

Sun Pharma Advanced Research Company

20 hours ago
bookmarkBookmark

Sun Pharma Advanced Research Company is a company. It is in Mumbai, India and it has a male CEO called Anilkumar Raghavan. It was founded in 2006 and is part of the Health Care sector, specifically in the Pharmaceuticals industry.

Key facts

plus See more facts
link LinkedIn
link X (Twitter): 51 followers


Extract data

Download datasets about Sun Pharma Advanced Research Company:

dataset Dataset of stocks from Sun Pharma Advanced Research Company:

Sun Pharma Advanced Research Company is one of the companies in India, companies in Pharmaceuticals, companies in Health Care, companies in Anilkumar Raghavan, companies in Mumbai and 3,456,835 companies in our database.

Talking Points

  • Sparc Life
  • Sun Pharma Advanced Research Company Limited (SPARC) is a clinical-stage biopharmaceutical company that focuses on developing innovative therapeutics to improve standards of care for patients worldwide.
  • Sun Pharma Advanced Research Company Ltd. (SPARC) is focused on improving standards of care for patients globally through innovation in therapeutics
  • Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited

Related

Connected or similar to Sun Pharma Advanced Research Company: .

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.